228 patents
Page 10 of 12
Utility
Modified Polynucleotides for the production of biologics and proteins associated with human disease
14 Sep 20
The invention relates to a pharmaceutical composition including a plurality of lipid nanoparticles having a mean particle size of between 80 nm and 160 nm and containing an mRNA encoding a polypeptide.
Stephane Bancel, Tirtha Chakraborty, Antonin De Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
Filed: 22 Oct 17
Utility
Betacoronavirus Mrna Vaccine
9 Sep 20
The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Sunny Himansu
Filed: 20 May 20
Utility
Epstein-barr Virus Vaccines
9 Sep 20
The disclosure relates to EBV ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Shinu John, Elisabeth Narayanan, Brooke Bollman
Filed: 19 Nov 18
Utility
Zika Virus Mrna Vaccines
2 Sep 20
Provided herein, in some embodiments, are Zika virus RNA vaccines and methods of producing an antigen-specific immune response in a subject.
Giuseppe Ciaramella, Sunny Himansu
Filed: 13 Apr 20
Utility
Polynucleotides Encoding Coagulation Factor VIII
26 Aug 20
The invention relates to mRNA therapy for the treatment of Hemophilia A. mRNAs for use in the invention, when administered in vivo, encode Factor VIII, isoforms thereof, functional fragments thereof, and fusion proteins comprising Factor VIII. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of Factor VIII expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient Factor VII I activity in subjects.
Raj Rajendran, Paolo G. V. Martini, Carol H. Miao
Filed: 12 Jun 18
Utility
Engineered nucleic acids and methods of use thereof
24 Aug 20
Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of microorganisms.
Stephane Bancel, Jason P. Schrum, Alexander Aristarkhov
Filed: 15 May 18
Utility
Messenger Ribonucleic Acids for Enhancing Immune Responses and Methods of Use Thereof
19 Aug 20
The disclosure features isolated mRNAs encoding a polypeptide that enhances immune responses to an antigen(s) of interest, such as polypeptides that activate Type I interferon pathway signaling or NFkB signaling, including mRNAs comprising one or more modified nucleobase.
Eric Yi-Chun HUANG, Sze-Wah TSE, Jared IACOVELLI, Kristine MCKINNEY, Kristen HOPSON
Filed: 31 Oct 19
Utility
Human Cytomegalovirus Rna Vaccines
5 Aug 20
The disclosure describes HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Shinu John, Kambiz Mousavi
Filed: 26 Mar 20
Utility
Modified Polynucleotides for the Production of Oncology-related Proteins and Peptides
5 Aug 20
The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
Antonin DE FOUGEROLLES, Justin GUILD
Filed: 8 Dec 19
Utility
Polynucleotides encoding relaxin
3 Aug 20
The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.
Barry Ticho, Nadege Briancon-Eris, Zhinan Xia, Athanasios Dousis, Seymour de Picciotto, Vladimir Presnyak, Stephen Hoge, Iain Mcfadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
Filed: 1 Jul 18
Utility
Analytical HPLC Methods
29 Jul 20
Aspects of the disclosure relate to liquid chromatography (e.g., HPLC) methods which enable high resolution separations of polynucleotides of various lengths, sequences, and/or base compositions in a highly tunable manner.
William Issa, Meredith Packer
Filed: 16 Aug 18
Utility
Human cytomegalovirus RNA vaccines
20 Jul 20
The disclosure describes HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Shinu John, Kambiz Mousavi
Filed: 23 Jun 19
Utility
Nucleic acid vaccines
13 Jul 20
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more antigens.
Giuseppe Ciaramella, Axel Bouchon, Eric Yi-Chun Huang
Filed: 26 Jul 18
Utility
CHIKV RNA vaccines
6 Jul 20
Aspects of the disclosure relate to nucleic acid vaccines.
Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
Filed: 14 Jun 18
Utility
HPIV3 RNA vaccines
6 Jul 20
The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Sunny Himansu
Filed: 27 Mar 19
Utility
Betacoronavirus mRNA vaccine
6 Jul 20
The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Sunny Himansu
Filed: 27 Feb 20
Utility
Modified polynucleotides for the production of secreted proteins
6 Jul 20
A pharmaceutical composition which has a plurality of lipid nanoparticles that has a mean particle size of between 80 nm and 160 nm and contains a modified mRNA encoding a polypeptide.
Antonin De Fougerolles, Justin Guild
Filed: 11 Jun 19
Utility
Modified Messenger Rna Comprising Functional Rna Elements
1 Jul 20
The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide a desired translational regulatory activity to the mRNA.
Melissa J. MOORE, Caroline KÖHRER, Ruchi JAIN, Vladimir PRESNYAK
Filed: 17 May 18
Utility
Human cytomegalovirus vaccine
29 Jun 20
The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Shinu John
Filed: 18 Apr 19
Utility
Respiratory Virus Vaccines
24 Jun 20
The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Sunny Himansu
Filed: 27 Feb 20